网站首页
概要
Interleukin 18 binding protein (IL-18 BP) is a glycoprotein that contains a single IgG domain (C2-type). In humans, alternative splicing of the mRNA results in at least four different isoforms being generated; the most-expressed form in humans is IL-18 BPa (Dinarello et al.; Kim et al.). IL-18 BPa inhibits pro-inflammatory cytokine IL-18 by preventing it from binding to its receptor, thereby inhibiting IL-18-induced IFN-gamma production; the binding of IL-18 BPa to IL-18 is primarily due to the Ig domain (Carrascal et al.; Dinarello et al.). IL-18 is associated with an increase in cell adhesion molecules, chemokine production, stimulating vascular endothelial cells, metastatic tumor cell invasion, autoimmune diseases, emphysema, metabolic syndromes, Crohn’s disease, psoriasis, and has also been implicated in a role in heart disease (Dinarello et al.). Some studies have also shown that blocking of IL-18 activity can reduce metastasis in mouse models of melanoma (Carrascal et al.).
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | Human Recombinant IL-18 BPa | 78209, 78209.1, 78209.2 | All | English |
| Safety Data Sheet | Human Recombinant IL-18 BPa | 78209, 78209.1, 78209.2 | All | English |
数据及文献
Data
(A) The biological activity of Human Recombinant IL-18 BPa was tested by its ability to inhibit proliferation of KG-1 cells in the presence of 50 ng/mL human IL-18. Inhibition of cell proliferation was measured using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation inhibition is at 50% of maximum. The EC50 in the above example is 20 ng/mL. (B) Human Recombinant IL-18 BPa was resolved with SDS-PAGE under reducing (+) conditions and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant IL-18 BPa has a predicted molecular mass of 17.6 kDa (monomer)or 35.2 kDa (dimer).
